Department of Internal Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.
Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
J Gastrointest Cancer. 2021 Mar;52(1):73-79. doi: 10.1007/s12029-020-00528-3. Epub 2020 Sep 30.
Patients with cancer might be at an increased risk of infection with COVID-19 and a more severe disease course. However, different tumor types have differing susceptibility to the infection and COVID-19 phenotypes. Thus, the risk and prevalence of COVID-19 is not uniform across the different tumor types. Here, we performed a meta-analysis to estimate the risk and prevalence of COVID-19 infection in colorectal cancer (CRC) patients.
A comprehensive literature search was performed up to July 25, 2020, thorough PubMed, Web of Science, Scopus, Google Scholar, CNKI, CBM, China Science, Wan Fang, and SciELO databases. The risk of COVID-19 infection in CRC patients was performed based on the odds ratios (ORs) and 95% confidence interval (95% CI).
A total of six studies with 204 different cancer patients with COVID-19 and 92 CRC infected patients with COVID-19 were selected. Our results showed that the prevalence of COVID-19 infection in CRC patients was 45.1% in the global population. The pooled data showed that there is no a significant risk of infection with COVID-19 in CRC patients in the global population (OR = 0.261, 95% CI 0.099-0.533, p = 0.082). However, when subgroup analysis was performed based on country of origin, we found a significant correlation in Chinese CRC patients (OR = 0.221, 95% CI 0.146-0.319, p ≤ 0.001).
This study results revealed that Chinese CRC patients harbored a higher risk of COVID-19 infection. However, more multicenter, larger sample sizes and high-quality studies are required to verify this meta-analysis result.
癌症患者可能面临感染 COVID-19 和更严重疾病过程的风险增加。然而，不同的肿瘤类型对感染和 COVID-19 表型的易感性不同。因此，不同肿瘤类型的 COVID-19 风险和流行率并不一致。在这里，我们进行了一项荟萃分析，以估计结直肠癌 (CRC) 患者感染 COVID-19 的风险和流行率。
我们全面检索了截至 2020 年 7 月 25 日的PubMed、Web of Science、Scopus、Google Scholar、CNKI、CBM、中国科学、万芳和 SciELO 数据库中的文献。通过优势比 (OR) 和 95%置信区间 (95%CI) 评估 CRC 患者感染 COVID-19 的风险。
共纳入 6 项研究，涉及 204 名不同癌症合并 COVID-19 患者和 92 名 CRC 合并 COVID-19 患者。结果显示，全球 CRC 患者合并 COVID-19 的感染率为 45.1%。汇总数据显示，全球人群中 CRC 患者感染 COVID-19 的风险无显著增加（OR=0.261，95%CI 0.099-0.533，p=0.082）。然而，根据来源国进行亚组分析时，我们发现中国 CRC 患者存在显著相关性（OR=0.221，95%CI 0.146-0.319，p≤0.001）。
本研究结果表明，中国 CRC 患者感染 COVID-19 的风险更高。然而，需要更多多中心、更大样本量和高质量的研究来验证本荟萃分析结果。
